Loading stock data…
Q32 Bio Inc (QTTB)
$11.69-0.30 (-2.50%)
Market ClosedLast close Sep 8
Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with alopecia areata and other autoimmune and inflammatory diseases driven by pathological immune dysfunction.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Q32 Bio Inc. in the Healthcare sector is trading at $11.69 with a market capitalization of $214M. Wall Street consensus targets $41.00 (5 analysts), implying a +250.7% move over the next 12 months. The stock is currently 50% below its 52-week high of $23.57, remaining 44.7% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. Risk note: RSI 19 is oversold, raising the odds of a near-term bounce. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +250.7% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Oversold momentum (RSI 19) — potential for technical mean-reversion
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0↓ | $53.74M | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$9.12M↓ | -$7.72M↓ | $45.88M↑ | -$7.58M↑ | -$9.17M |
| Net Income | -$8.95M↓ | -$7.61M↓ | $57.73M↑ | -$7.39M↑ | -$9.49M |
Peer Comparison
JNJUNHPFE
Fundamentals
Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with alopecia areata and other autoimmune and inflammatory diseases driven by pathological immune dysfunction. The company is...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$214.50M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
71.78%
Volume
Today's trading volume
592,918
Recent News
Down 23.1% in 4 Weeks, Here's Why Q32 Bio (QTTB) Looks Ripe for a Turnaround
The heavy selling pressure might have exhausted for Q32 Bio (QTTB) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
These 2 ‘Monster Growth’ Stocks Aren’t Done Climbing, Say Analysts
Ask any old-school market investor and he’ll tell you that the cliché is true, and ‘past performance cannot guarantee future returns.’ If that were true without exception, then growth investing would not be a viable option – but we all know that investors love to buy into stocks that have shown enormous growth in recent months. The ‘monster growth’ stocks are popular because investing into them is successful. The key is understanding the smart middle way, and treating stocks as individuals, with
Wall Street Analysts See an 182.18% Upside in Q32 Bio (QTTB): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 182.2% in Q32 Bio (QTTB). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Wall Street Analysts Think Q32 Bio (QTTB) Could Surge 185.99%: Read This Before Placing a Bet
The consensus price target hints at an 186% upside potential for Q32 Bio (QTTB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Are You Looking for a Top Momentum Pick? Why Q32 Bio (QTTB) is a Great Choice
Does Q32 Bio (QTTB) have what it takes to be a top stock pick for momentum investors? Let's find out.